DE69626301D1 - Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen - Google Patents

Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen

Info

Publication number
DE69626301D1
DE69626301D1 DE69626301T DE69626301T DE69626301D1 DE 69626301 D1 DE69626301 D1 DE 69626301D1 DE 69626301 T DE69626301 T DE 69626301T DE 69626301 T DE69626301 T DE 69626301T DE 69626301 D1 DE69626301 D1 DE 69626301D1
Authority
DE
Germany
Prior art keywords
terbinafin
medicine
pylori infection
producing
helicobacter pylori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69626301T
Other languages
English (en)
Other versions
DE69626301T2 (de
Inventor
Ivan James Dalton Lindley
Neil Stewart Ryder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69626301D1 publication Critical patent/DE69626301D1/de
Application granted granted Critical
Publication of DE69626301T2 publication Critical patent/DE69626301T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
DE69626301T 1995-07-06 1996-07-05 Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen Expired - Lifetime DE69626301T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513750.1A GB9513750D0 (en) 1995-07-06 1995-07-06 Use of allylamines
PCT/EP1996/002970 WO1997002026A1 (en) 1995-07-06 1996-07-05 Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases

Publications (2)

Publication Number Publication Date
DE69626301D1 true DE69626301D1 (de) 2003-03-27
DE69626301T2 DE69626301T2 (de) 2003-10-16

Family

ID=10777201

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69626301T Expired - Lifetime DE69626301T2 (de) 1995-07-06 1996-07-05 Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen

Country Status (27)

Country Link
US (1) US5935998A (de)
EP (1) EP0863752B1 (de)
JP (1) JP3680950B2 (de)
KR (1) KR100425401B1 (de)
CN (1) CN1204881C (de)
AT (1) ATE232723T1 (de)
AU (1) AU715270B2 (de)
CA (1) CA2219678C (de)
CY (1) CY2465B1 (de)
CZ (1) CZ289440B6 (de)
DE (1) DE69626301T2 (de)
DK (1) DK0863752T3 (de)
ES (1) ES2192608T3 (de)
GB (1) GB9513750D0 (de)
HK (1) HK1011527A1 (de)
HU (1) HU224311B1 (de)
IL (1) IL122853A (de)
MX (1) MX9710093A (de)
MY (1) MY132436A (de)
NO (1) NO317496B1 (de)
PL (1) PL187704B1 (de)
RU (1) RU2193402C2 (de)
SI (1) SI0863752T1 (de)
SK (1) SK282874B6 (de)
TW (1) TW522011B (de)
WO (1) WO1997002026A1 (de)
ZA (1) ZA965749B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001315D0 (en) * 2000-01-20 2000-03-08 Novartis Ag Organic compounds
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
KR20030066186A (ko) * 2002-02-05 2003-08-09 한솔케미언스 주식회사 (ｅ)-터비나핀 또는 이의 염산염의 제조방법
DE602004028284D1 (de) 2003-12-08 2010-09-02 Cpex Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2716943C2 (de) * 1976-04-28 1986-08-14 Sandoz-Patent-GmbH, 7850 Lörrach N-(3-Phenyl-2-propenyl)-N-(1-naphthylmethyl)-amine, ihre Verwendung und Herstellung
DE2862103D1 (en) * 1977-08-19 1982-11-18 Sandoz Ag Propenyl amines, processes for their production and pharmaceutical compositions containing them
DE3020113A1 (de) * 1979-06-08 1980-12-18 Sandoz Ag 2-(1-naphthyl)piperidin-derivat, dessen herstellung sowie die verwendung als antimykotika
EP0024587B1 (de) * 1979-08-22 1984-11-14 Sandoz Ag Propenylamine, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung als Arzneimittel
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4894375A (en) * 1986-09-29 1990-01-16 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
CA2020888A1 (en) * 1989-07-27 1991-01-28 Philippe Guerry Substituted aminoalkoxybenzene derivatives
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
DE4317449A1 (de) * 1993-05-19 1994-11-24 Asche Ag Arzneimittel zur Behandlung von Erkrankungen des Magen-Darm-Traktes

Also Published As

Publication number Publication date
MX9710093A (es) 1998-03-31
IL122853A (en) 2001-04-30
KR19990028725A (ko) 1999-04-15
ZA965749B (en) 1998-01-05
IL122853A0 (en) 1998-08-16
NO975790D0 (no) 1997-12-09
AU715270B2 (en) 2000-01-20
RU2193402C2 (ru) 2002-11-27
SI0863752T1 (en) 2003-06-30
ES2192608T3 (es) 2003-10-16
EP0863752A1 (de) 1998-09-16
PL323305A1 (en) 1998-03-16
NO317496B1 (no) 2004-11-08
HK1011527A1 (en) 1999-07-16
CA2219678C (en) 2006-10-10
CN1189775A (zh) 1998-08-05
CZ1798A3 (cs) 1998-03-18
HUP9802929A3 (en) 1999-10-28
CN1204881C (zh) 2005-06-08
CA2219678A1 (en) 1997-01-23
KR100425401B1 (ko) 2004-07-16
MY132436A (en) 2007-10-31
HU224311B1 (hu) 2005-07-28
PL187704B1 (pl) 2004-09-30
GB9513750D0 (en) 1995-09-06
CY2465B1 (en) 2005-06-03
JP3680950B2 (ja) 2005-08-10
EP0863752B1 (de) 2003-02-19
US5935998A (en) 1999-08-10
JPH11508580A (ja) 1999-07-27
DE69626301T2 (de) 2003-10-16
SK282874B6 (sk) 2003-01-09
ATE232723T1 (de) 2003-03-15
SK698A3 (en) 1998-05-06
TW522011B (en) 2003-03-01
AU6519596A (en) 1997-02-05
NO975790L (no) 1997-12-09
WO1997002026A1 (en) 1997-01-23
HUP9802929A2 (hu) 1999-09-28
CZ289440B6 (cs) 2002-01-16
DK0863752T3 (da) 2003-04-22

Similar Documents

Publication Publication Date Title
DE59511017D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
DE69429078T2 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
DE69601345D1 (de) Propiophenon-Derivate und Verfahren zur ihrer Herstellung
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
ATE189601T1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE69626301D1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
DE3878111T2 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
ATE216237T1 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
ATE183390T1 (de) Verwendung einer kombination von antineoplastonen zur herstellung eines arzneimittels zur behandlung der neurofibromatose
ATE143946T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE240101T1 (de) Verwendung von 2-phenyl-3- aroylbenzothiophenderivaten zur herstellung eines medikaments zur knochen- und bruchheilung
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE200623T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

R082 Change of representative

Ref document number: 863752

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE